The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves IVIG to Treat Adults with Dermatomyositis

FDA Approves IVIG to Treat Adults with Dermatomyositis

August 17, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On July 15, the U.S. Food & Drug Administration (FDA) approved a 10% solution of a human intravenous immunoglobulin (IVIG), Octagam 10%, to treat adults with dermatomyositis, a rare chronic systemic autoimmune disease with a characteristic skin rash and progressive proximal muscle weakness.1,2 This treatment was previously FDA approved to treat chronic immune thrombocytopenic purpura.3

You Might Also Like
  • FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
  • Health Canada Approves Upadacitinib to Treat Adults with PsA
Explore This Issue
September 2021
Also By This Author
  • TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?

The current FDA approval was based on results of the international, multi-center study Progress in Dermatomyositis (ProDERM) study. Data from this phase 3, randomized, double-blind, placebo-controlled trial were presented during the 2021 virtual EULAR Congress, June 2–5, by Rohit Aggarwal, MD, MS, associate professor of medicine at the University of Pittsburgh, medical director of the Arthritis and Autoimmunity Center and co-director of the Myositis Center.4 The goal of the study (NCT02728752) was to evaluate the safety, tolerability and efficacy of IVIG in dermatomyositis patients.5

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study’s primary endpoint was the proportion of patients who responded to IVIG treatment compared with the proportion of patients who responded to placebo at week 16. Per the 2016 ACR/EULAR myositis response criteria, response was defined as a minimal improvement in total improvement score (TIS) of at least 20 points and no clinical worsening at two consecutive visits up to week 16.

The first part of the study lasted for 16 weeks. It was the double-blind, placebo-controlled period during which adult patients with definite or probable dermatomyositis were randomized 1:1 to receive either high-dose IVIG (2 g/kg of body weight) every four weeks or placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the second part of the study, patients treated with placebo and patients who did not have clinical worsening while receiving IVIG entered a 24-week, open-label extension period. These patients received 2 g/kg of body weight of IVIG every four weeks. Patients who were stable at week 28 could have their dose reduced to 1 g/kg of body weight every four weeks. Patients with clinical worsening at two consecutive visits between weeks 8 and 16 were switched to the alternate treatment arm.

The Results

A total of 95 adults with a mean age of 53 years were enrolled in ProDERM. The patients were predominantly white (92%) women (75%). Their baseline clinical characteristics, including medical history and prior dermatomyositis treatment, were well balanced between the IVIG treatment group (n=47) and the placebo group (n=48).

At week 16, the primary study endpoint was met, with 78.7% of IVIG-treated patients responding to treatment compared with 43.8% of placebo-treated patients. This difference of 34.9% was considered significant (95% confidence interval [CI] 16.70–53.24; P=0.0008).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: dermatomyositis, dermatomyositis (DM), FDA, FDA approval, immunoglobulin, intravenous human immunoglobulin, Octagam 10%, U.S. Food and Drug Administration (FDA)Issue: September 2021

You Might Also Like:
  • FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
  • Health Canada Approves Upadacitinib to Treat Adults with PsA
  • Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)